Expanscience Mexico is a wholly owned subsidiary of privately-owned French pharmaceutical company, Laboratoires Expanscience S.A. ('Expanscience') which already holds Maxigesic rights for France.
Maxigesic consists of a patented, fixed ratio of ibuprofen for anti-inflammation management and paracetamol (also called acetaminophen) for pain management. Maxigesic products covered by the new licensing agreement include tablet, oral liquid, fast-dissolve and dry powder sachets.
AFT Managing Director, Dr Hartley Atkinson, says that he is very pleased to further extend the company's partnership with Expanscience.
'We had previously disclosed our target to sell Maxigesic to 100 countries in the disclosure statement. As a result of this latest partnership with Expanscience, we have now further increased our agreements to some 125 countries. Importantly we've now added our first market in North America. Mexico is the fifteenth largest market in the world for sales of Paracetamol tablets and of Ibuprofen oral tablets.'
'Although we will need to complete product registrations in Mexico in the near future, we anticipate sales to commence within the FY19 time period. As previously noted, we have experienced some delays in launches due to regulatory delays in various countries, but the number of Maxigesic launches to occur within the FY19 time period is increasing with over 30 new launches anticipated.'
We believe that Mexico represents good potential for Maxigesic as the market defined by IMS Health for paracetamol tablet and ibuprofen tablet sales in Mexico is close to an aggregate of US$200M.'
Ferghana Partners (New York, London, Boston) initiated these transactions and provided strategic/financial advisory services to AFT Pharma.
About Expanscience Mexico SA
Laboratorios Expanscience Mexico, S.A. DE C.V., a company incorporated in Mexico and having its registered office at Blvd Miguel Cervantes de Saavedra 233, Colonia Grenada, C.P. 11520 México and wholly owned subsidiary of Laboratoires Expanscience is a pharmaceutical company incorporated in France having its registered office at 1 Place des Saisons 92048 Paris La Defense Cedex, Paris, France
AFT Pharmaceuticals Limited published this content on 19 January 2018 and is solely responsible for the information contained herein.
Distributed by Public, unedited and unaltered, on 19 January 2018 00:44:06 UTC.
Original documenthttps://www.aftpharm.com/news/aft-pharmaceuticals-painkiller-maxigesic-now-licensed-in-mexico-taking-licensed-countries-to-125/
Public permalinkhttp://www.publicnow.com/view/006D89824073A0E37C2EB82407058FBBC669D4D3
